Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(100.0%)
2Total
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07077642Enrolling By Invitation

Validation of a Multidimensional Scale for the Detection of Health Needs in People With HIV

Role: lead

NCT03163277Phase 4Terminated

Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)

Role: lead

NCT01902186Phase 4Terminated

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir

Role: lead

NCT01406093Completed

Early- and Late-onset Candidemia

Role: lead

All 4 trials loaded